Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. on December 22, 2021. The report details the completion of a significant asset transaction following the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on December 20, 2021.
Key Financial Metrics
The filing reports a one-time cash inflow resulting from the sale of a regulatory asset. The Company received $110.0 million in cash upon the closing of the Asset Sale. The filing does not provide comprehensive revenue, profit, operating cash flow, margin, debt, or liquidity metrics for the reporting period, as this is a current report focused on a specific event rather than a periodic financial statement.
Material Changes
The primary material change is the disposition of the Company's Rare Pediatric Disease Priority Review Voucher (PRV). This asset was awarded by the U.S. Food and Drug Administration on September 29, 2021, in connection with the approval of LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome. The Company sold this PRV to Janssen Biotech, Inc., an affiliate of Johnson & Johnson.
Outlook, Risks, and Management Commentary
Management confirmed the transaction was executed pursuant to an Asset Purchase Agreement dated November 16, 2021. The filing notes that the description of terms is qualified by reference to the full agreement filed as Exhibit 10.1 to a prior 8-K. No specific forward-looking guidance, risk factors, or contingencies beyond the standard regulatory waiting period expiration are detailed in this specific text.
Key Facts for Investor Verification
- Transaction Type: Sale of a Priority Review Voucher (PRV).
- Counterparty: Janssen Biotech, Inc. (Johnson & Johnson affiliate).
- Cash Proceeds: $110.0 million received at closing.
- Underlying Asset: PRV awarded for LIVMARLI (maralixibat) approval for Alagille syndrome.
- Closing Date: December 20, 2021.